Longeveron

Longeveron(LGVN)

MIAMI, FL
Biotechnology

Focus: Stem Cells to combat aging

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Through patient-focused, regenerative medicine, our research and therapies are aimed at improving healthspan.

Cell Therapy
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Longeveron Mesenchymal Stem Cells
Alzheimer's Disease
Phase 1
Clinical Trials (1)
NCT02600130Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
Phase 1
Longeveron Mesenchymal Stem Cells
ARDS, Human
Phase 1
Clinical Trials (1)
NCT04629105Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)
Phase 1
Clinical Trials (1)
NCT02398604Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
Phase 1
Longeveron Mesenchymal Stem Cells
HLHS
Phase 1/2
Clinical Trials (1)
NCT03525418Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)
Phase 1/2
Allogeneic Human Mesenchymal Stem Cells
Frailty
Phase 1/2
Clinical Trials (1)
NCT02065245AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
Phase 1/2
Longeveron Mesenchymal Stem Cells
Aging Frailty
Phase 1/2
Clinical Trials (1)
NCT02982915Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
Phase 1/2
Lomecel-B medicinal signaling cells
Hypoplastic Left Heart Syndrome
Phase 2
Clinical Trials (1)
NCT04925024Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Phase 2
Phase 2
Clinical Trials (1)
NCT05233774Lomecel-B Effects on Alzheimer's Disease
Phase 2
Peripheral Intravenous
Metabolic Disease
Phase 2
Clinical Trials (1)
NCT02587572Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial
Phase 2
Longeveron Mesenchymal Stem Cells
Aging Frailty
Phase 2
Clinical Trials (1)
NCT03169231Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 10 clinical trials
Top TAs: Neurology, Infectious Diseases
Publications: 12 in PubMed
SEC Filings: 2 available
Therapeutic Area Focus
Neurology
2 pipeline
Marketed
Pipeline

Financials (FY2024)

Revenue
$709K42%
R&D Spend
$9M(1279%)3%
Net Income
-$21M
Cash
$5M

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles